MedPlus Health Services Ltd Q2FY26 – India’s Pharmacy Empire Pops a Profit Pill: 43% PAT Surge, 4,552 Stores, and Drug License Suspensions More Frequent Than Netflix Releases
1. At a Glance
If you think retail pharma is boring, you haven’t met MedPlus Health Services Ltd, India’s #2 largest pharmacy chain (after Apollo), now scripting an operational miracle with over 4,552 stores across 12 states and 1 UT — and about as many regulatory notices.
At ₹763/share (market cap ₹9,163 crore), MedPlus is the kind of company that makes analysts say, “Margins bad hain, lekin growth dekh yaar!” Q2FY26 saw revenue hit ₹1,679 crore (+6.5% YoY) and PAT ₹55.5 crore (+43.3% YoY). That’s faster profit growth than your family WhatsApp group forwarding home remedies.
With an OPM of 8.7%, P/E of 47x, and a Debt-to-Equity ratio of 0.65, the balance sheet looks healthy — though it could use a multivitamin boost in ROE (8.8%). The company’s 94.6% profit growth (TTM) suggests operational steroids are working.
The pharmacy network adds 108 new stores a quarter, spreading faster than monsoon fever, and 71 of those were in Tier-2/3 cities — because even smaller towns now want cashback on Crocin.
So, here’s the prescription: steady top-line, improving margins, but recurring license headaches. Will MedPlus be India’s next Apollo… or another case of chronic compliance fatigue? Let’s diagnose.
2. Introduction
In a country where your neighborhood chemist can mispronounce “paracetamol” but remember your entire family’s BP readings, MedPlus is trying to formalize chaos.
Founded in 2006 by Dr. Madhukar Gangadi, MedPlus was built around a simple idea: “What if your local medical store actually gave bills?” Fast forward to FY26, and the brand operates one of the most tightly integrated pharmacy retail networks in India — a mix of physical stores, online platforms, and diagnostic services.
They’re not selling just pills. They’re selling peace of mind, conveniently discounted and delivered within two hours to 2,709 pin codes. It’s the Flipkart-ification of pharmacy — except instead of smartphones, they deliver your cholesterol control tablets.
MedPlus stores are like neighborhood landmarks — brightly lit, well-stocked, and algorithmically optimized. Their model is 95% company-owned (no franchise chaos), sourcing 80% directly from manufacturers — meaning margins are real, not theoretical.
And yet, while they were filling prescriptions, the stock market started filling doubts: why the 59% promoter pledge, why the low ROE, and why do regulators seem to suspend their licenses more often than we skip leg day?
Time to open the financial cabinet.
3. Business Model – WTF Do They Even Do?
MedPlus operates on the “pharmacy + FMCG + diagnostics” triad. Think of it as a prescription with a dash of soap, glucose, and blood reports.
1️ Retail Pharmacy – The Core Pill
4,552 stores across 12 states and 1 UT.
51% metro, 49% non-metro revenue mix.
Product mix (Q2FY25):
Branded Pharma: 67.2%
Private Label Pharma: 10.5%
Branded FMCG: 10.7%
Private Label FMCG: 7.9%
Private labels are the magic pills — 1,164 products so far — higher margins, better customer stickiness, and less dependency on Cipla and Dr. Reddy’s moods.
2️ FMCG – The Margin Booster
Soaps, lotions, and home care — all low-ticket, high-velocity items. FMCG isn’t just “side income”; it’s the painkiller for pharma’s thin margins.
3️ Diagnostics – The New Shot
They now run 3 full-service diagnostic centers, 4 Level-2 labs, and 110 collection centers. Small today, but if you know India’s healthcare trendline, this could be the next growth injection.
Digital Play
Their MedPlus Mart app and website clock 5% of total revenue. With a 2-hour delivery promise and 630 fulfillment hubs, it’s like Swiggy for supplements.
Business philosophy? “Discount on chronic meds, loyalty on acute meds.” Essentially, they hook customers with cheap BP tablets and upsell shampoo.
